Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 8;22(5):2739.
doi: 10.3390/ijms22052739.

Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Affiliations
Review

Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Birgitta Strandvik. Int J Mol Sci. .

Abstract

While approximately 2000 mutations have been discovered in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR), only a small amount (about 10%) is associated with clinical cystic fibrosis (CF) disease. The discovery of the association between CFTR and the hyperactive epithelial sodium channel (ENaC) has raised the question of the influence of ENaC on the clinical CF phenotype. ENaC disturbance contributes to the pathological secretion, and overexpression of one ENaC subunit, the β-unit, can give a CF-like phenotype in mice with normal acting CFTR. The development of ENaC channel modulators is now in progress. Both CFTR and ENaC are located in the cell membrane and are influenced by its lipid configuration. Recent studies have emphasized the importance of the interaction of lipids and these proteins in the membranes. Linoleic acid deficiency is the most prevailing lipid abnormality in CF, and linoleic acid is an important constituent of membranes. The influence on sodium excretion by linoleic acid supplementation indicates that lipid-protein interaction is of importance for the clinical pathophysiology in CF. Further studies of this association can imply a simple clinical adjuvant in CF therapy.

Keywords: CFTR; linoleic acid; renal excretion; sodium; supplementation; sweat.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Savant A.P., McColley S.A. Cystic fibrosis year in review 2019: Section 1. CFTR modulators. Pediatr. Pulmonol. 2020;55:3236–3242. doi: 10.1002/ppul.25039. - DOI - PubMed
    1. Fonseca C., Bicker J., Alves G., Falcão A., Fortuna A. Cystic fibrosis: Physiopathology and the latest pharmacological treatments. Pharmacol. Res. 2020;162:105267. doi: 10.1016/j.phrs.2020.105267. - DOI - PubMed
    1. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr. Pulmonol. 1995;20:63–70. doi: 10.1002/ppul.1950200203. - DOI - PubMed
    1. Tirouvanziam R., de Bentzmann S., Hubeau C., Hinnrasky J., Jacquot J., Péault B., Pucelle E. Inflammation and infection in naïve human cystic fibrosis airway grafts. Am. J. Resp. Cell Mol. Biol. 2000;23:121–127. doi: 10.1165/ajrcmb.23.2.4214. - DOI - PubMed
    1. Tirouvanziam R., Khazaal I., Peault B. Primary inflammation in human cystic fibrosis small airways. Am. J. Physiol. Lung Cell Mol. Physiol. 2002;283:L445–L451. doi: 10.1152/ajplung.00419.2001. - DOI - PubMed

MeSH terms

Substances